NEW DELHI: Drug firm BDR Pharmaceuticals on Monday said it has launched 80 mg version of generic enzalutamide pills frail for the medication of prostate most cancers in India at a tag of Rs 24,480 per pack with 4 strips.
The firm had earlier bought approval from the Treatment Controller Frequent of India (DCGI) to design 40 mg enzalutamide in 2017 to treat men with metastatic castration-resistant prostate most cancers (mCRPC) below the stamp title Bdenza, BDR Pharma said in a assertion.
The 80 mg version is an strive and decrease the tablet burden as it’s expected to enlarge the affected person compliance, it added.
“At BDR Pharma, we blueprint to introduce modern medication alternate choices that will income most cancers patients and abet their overall normal of care. This delivery further strengthens our dedication to give practical and accessible medication alternate choices for patients with prostate most cancers in India,” BDR Pharma CMD Dharmesh Shah said.
The drug is being launched at a tag of Rs 24,480 for one pack with 4 strips. Every strip has 14 pills, the firm said.
Prostate most cancers is one of many leading cancers in India, which time and another time affects men within the age community of over 65 years, the assertion said.